A Phase 2 clinical trial evaluating ASP5541 in participants with prostate cancer was listed as recruiting on August 21, 2026. The study, registered as NCT07005154, is titled "A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer."
According to the trial record, the study is currently in the recruiting phase, meaning it is enrolling participants who meet its criteria. The trial is designated as Phase 2, a stage typically used to further assess a compound in a defined patient population.
No results have been posted for this trial as of the listed date. The record does not include information on outcomes, efficacy, or safety findings at this stage. This brief reflects only the recruitment status and phase designation as documented in the trial registration.
Corticotropin, associated with ASP5541 in this listing, remains an approved compound according to its regulatory status. Readers interested in additional background on this compound can consult the compound overview for further context.